Comparison of Antibody Titers From COVID-19 Survivors and Health Workers Getting Two Doses of the Sinovac® Vaccine
Abstract
Almost two years since becoming a global threat, the whole world is still looking for the best way to reduce the rate of transmission of COVID-19. One of the ways to deal with COVID-19 is to increase immunity by stimulating antibodies in the community. Antibody-mediated humoral responses are critical to prevent viral infections. Antibodies can also be formed through natural processes when someone is infected by SARS-Cov2 or through vaccination programs. In this study, collective blood samples were taken to examine IgG spike receptor binding domains (IgG S-RBD) between two groups: COVID-19 survivors (n = 50) and health workers who were vaccinated twice with the Sinovac vaccine (n = 50). There were no significant differences in antibody levels between the previous COVID-19 infection group and the health workers groups (p = 0.8). 50% (n = 6) of the health workers who were aged 30-39 had excellent titer antibody levels, as did 50% (n=7) of the COVID-19 survivors group who were in their 30s. Further research is needed to decide the perfect time for booster shots.
Keywords: COVID-19, titer antibody, IgG S-RBD, Sinovac
References
[1] WHO Coronavirus (COVID-19) Dashboard _ WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. World Health Organization.
[2] Stephens DS, McElrath MJ. COVID-19 and the path to immunity. JAMA - Journal of the American Medical Association. 2020;324:1279–81.
[3] Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. What level of neutralising antibody protects from COVID-19?. Available from: https://doi.org/10.1101/2021.03.09.21252641.
[4] Kaur SP, Gupta V. COVID-19 vaccine: A comprehensive status report. Virus Research. Elsevier B.V.; 2020.
[5] Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020 Apr;181(2):281– 292.e6.
[6] Gralinski LE, Menachery VD. Return of the coronavirus: 2019-nCoV. Volume 12. Viruses. MDPI AG; 2020.
[7] He Y, Zhou Y, Siddiqui P, Jiang S. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem Biophys Res Commun. 2004 Dec;325(2):445–52.
[8] Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature. 2004 Apr;428(6982):561–4.
[9] Min L, Sun Q. Antibodies and Vaccines Target RBD of SARS-CoV-2. Frontiers in Molecular Biosciences. Frontiers Media S.A.; 2021.
[10] Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science (1979). 2021 Feb 5;371(6529).
[11] Chowdhury MA, Hossain N, Kashem MA, Shahid MA, Alam A. Immune response in COVID-19: A review. Journal of Infection and Public Health. Elsevier Ltd. 2020;13:1619–29.
[12] Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice [Internet]. 2004. Available from: www.cdc.govmmwrmguidesars.html
[13] Bukreyev A, Lamirande EW, Buchholz UJ, Vogel LN, Elkins WR, St Claire M, et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS [Internet]. Lancet. 2004 Jun;363(9427):2122–7. [cited 2022 Apr 24] Available from: https://pubmed.ncbi.nlm.nih.gov/15220033/